Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)-Reference-Cited by-同舟云学术

Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study)

Published:2012-12-05 Issue:5 Volume:23 Page:1250-1259
ISSN:0938-7994
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Deray Gilbert,Rouviere Olivier,Bacigalupo Lorenzo,Maes Bart,Hannedouche Thierry,Vrtovsnik François,Rigothier Claire,Billiouw Jean-Marie,Campioni Paolo,Ferreiros Joaquin,Devos Daniel,Alison Daniel,Glowacki François,Boffa Jean-Jacques,Marti-Bonmati Luis

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00330-012-2705-x

Reference25 articles.

1. Stacul F, van der Molen AJ, Reimer P et al (2011) on behalf of the Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 21:2527–2541

2. Rao QA, Newhouse JH (2006) Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. Radiology 239:392–397

3. Penfield JG, Reilly RF Jr (2007) What nephrologists need to know about gadolinium. Nat Clin Pract Nephrol 3:654–668

4. Perazella MA (2008) Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 3:67–75

5. Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G (2009) Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 250:618–628

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Feasibility and safety of contrast-enhanced magnetic resonance-guided adaptive radiotherapy for upper abdominal tumors: A preliminary exploration;Physics and Imaging in Radiation Oncology;2024-04

2. Protein MRI Contrast Agents as an Effective Approach for Precision Molecular Imaging;Investigative Radiology;2024-02

3. Safety profile of Gadoterate meglumine on the renal function of patients with severe kidney disease;Clinical Imaging;2022-11

4. Gadolinium-based contrast agents for imaging of the central nervous system: A multicenter European prospective study;Medicine;2022-08-26

5. A risk prediction model for contrast-induced nephropathy associated with gadolinium-based contrast agents;Renal Failure;2022-05-04